PRACTICE AID Emerging Treatments for Neovascular AMD
This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients.
Next-Generation Anti-VEGF Agents
Treatment MOA Mode of Delivery Status Humanized, single-chain antibody fragment inhibitor of Positive Brolucizumab1-3 Intravitreal VEGF-A combined with the use phase 3 data of a sustained-delivery system Ankyrin repeating protein Phase 3 Abicipar pegol4-6 (DARPin); antagonist to all Intravitreal underway isoforms of VEGF-A Approved in Recombinant human VEGF Conbercept7 Intravitreal China, phase 4 receptor-Fc fusion protein underway
Agents Targeting the Angiopoietin/Tie2 Pathway
Treatment MOA Mode of Delivery Status No longer Nesvacumab8 Angiopoietin-2 antibody Intravitreal under development
Anti-VEGF/anti-angiopoietin-2 Phase 2 RG77169 Intravitreal bispecific antibody studies completed
Access the activity, “Updates in Neovascular Age-Related Macular Degeneration: Improving Detection, Reducing the Burden of Treatment, and Optimizing Visual Outcomes,” at www.peerview.com/AMD2018. PRACTICE AID Emerging Treatments for Neovascular AMD
Other Investigational Therapies
Treatment MOA Mode of Delivery Status Phase 2b in Intravitreal combination with OPT-30210 VEGF-C/D “Trap” therapy injection ranibizumab underway Interrupts and reverses Clinical trials Squalamine11 Topical angiogenesis failed Positive phase 2a Anti-tissue factor ICON-112 Intravitreal data (combination immunoconjugate protein with ranibizumab) Positive phase PAN-9080613 Anti-VEGF Topical 1/2 data Intravitreal depot Phase 1/2 GB-10214 Tyrosine kinase inhibitor formulation underway
AMD: age-related macular degeneration; DARPin: designed ankyrin repeat proteins; DME: diabetic macular edema; DR: diabetic retinopathy; Fc: fragment crystallizable; MOA: mechanism of action; VE-PTP: vascular endothelial-protein tyrosine phosphatase. 1. Dugel P et al. American Academy of Ophthalmology 2017 Annual Meeting. Abstract 69. 2. http://www.mdmag.com/medical-news/brolucizumab-meets-endpoints-in-phase-iii-trials. Accessed March 28, 2018. 3. http://retinatoday.com/2016/06/a-novel-compound-for-treatment-of-wet-amd/. Accessed March 28, 2018. 4. Michalska-Małecka K et al. Eur Geriatr Med. 2015;6:69-75. 5. Cook HL et al. Br Med Bull. 2008;85:127-149. 6. http://www.scienceofamd.org/positive-phase-2-trial-results-of-anti-vegf-abicipar-pegol-for-treating-wet-amd/. Accessed March 28, 2018. 7. Lu X, Sun X. Drug Des Devel Ther. 2015;9:2311-2320. 8. https://www.prnewswire.com/news-releases/regeneron-provides-update-on-eylea-aflibercept-injection-and-nesvacumab-ang2-antibody- combination-program-300561643.html. Accessed April 8, 2018. 9. https://www.clinicaltrials.gov/ct2/show/NCT03038880?term=RG7716&cond=Neovascular+Age-related+Macular+Degeneration&ra nk=1. Accessed April 8, 2018. 10. https://www.clinicaltrials.gov/ct2/show/NCT03345082?term=opt-302&cond=Neovascular+Age-related+Macular+Degeneration&rank=1. Accessed April 8, 2018. 11. https://www.visionaware.org/blog/visionaware-blog/clinical-trial-update-squalamine-eye-drops-for-wet-macular-degeneration/12. Accessed April 8, 2018. 12. Gonzales C. Association for Research in Vision and Ophthalmology 2017 Annual Meeting (ARVO 2017). Abstract 3766. 13. Chaney P. 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology. https://ois.net/ois- aao-2015/presentations/. Accessed April 17, 2018. 14. https://www.clinicaltrials.gov/ct2/show/NCT03249740?term=GB-102&cond=Neovascular+Age-related+Macular+Degeneration&rank=1. Accessed April 8, 2018. Access the activity, “Updates in Neovascular Age-Related Macular Degeneration: Improving Detection, Reducing the Burden of Treatment, and Optimizing Visual Outcomes,” at www.peerview.com/AMD2018.